DLL4 and cancer: With the discovery that DLL4+ Mo-LCs most potently activated T cells among the monocyte-derived cells (Figure 6), targeting DLL4+ Mo-LCs may offer a promising therapeutic strategy such as in cancer treatment (24, 27, 35, 57, 60).